Viruses for the treatment of cellular proliferative disorders

Details Viruses for the treatment of cellular proliferative disorders Viruses for the treatment of cellular proliferative disorders

2007-08-07

2007-08-07

Campell, Bruce R. (Department: 1648)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

C435S320100

Reexamination Certificate

active

10418290

ABSTRACT:
Methods for treating cell proliferative disorders by administering virus to proliferating cells having an activated Ras-pathway are disclosed. The virus is administered so that it ultimately directly contacts proliferating cells having an activated Ras-pathway. Proliferative disorders include but are not limited to neoplasms. The virus is selected from modified adenovirus, modified HSV, modified vaccinia virus and modified parapoxvirus orf virus. Also disclosed are methods for treating cell proliferative disorders by further administering a immunosuppressive agent.

REFERENCES:
patent: 5585096 (1996-12-01), Martuza et al.
patent: 5856181 (1999-01-01), McCormick
patent: 6245543 (2001-06-01), Drake et al.
patent: 6649157 (2003-11-01), Coffey et al.
patent: 0514603 (1992-11-01), None
patent: WO 96/00007 (1996-01-01), None
patent: WO 97/12623 (1997-04-01), None
patent: WO 97/37031 (1997-10-01), None
patent: WO 98/50063 (1998-11-01), None
patent: WO 99/08692 (1999-02-01), None
patent: WO 99/18799 (1999-04-01), None
patent: WO 99/45783 (1999-09-01), None
patent: WO 99/67372 (1999-12-01), None
Williams B. Oncogene 1999, vol. 18, pp. 6112-6120.
Strong et al. The EMBO J. 1998, vol. 17, No. 12, pp. 335-3362.
He et al. J.Virol. 1997, vol. 71, No. 8, pp. 6049-6054.
Toyoizumi et al. Human Gene Ther. 1999, vol. 10, pp. 3013-3029.
Alemany, et al.,Cancer Gene Ther. (1999) 6:21-25.
Barbacid, M.,A Rev. Biochem. (1987) 56:779-827.
Beattie, E., et al.,Virology(1991) 183:419-422.
Black, T.L., et al.,J. Virol. (1993) 67:791-800.
Bos, J.,Cancer Res. (1989) 49:4682.
Kevin A. Cassady, et al., “The Second-Site Mutation in the Herpes Simplex Virus Recombinants Lacking the γ134.5 Genes Precludes Shutoff of Protein Synthesis by Blocking the Phosphorylation of eIF-2α,”J. of Virology, vol. 72, No. 9, 1998, pp. 7005-7011.
Chang, H.W. and Jacobs, B. L.,Virology(1993) 194:537-547.
Chaubert P., et al.,Am. J. Path. (1994) 144:767-775.
Chong, K. L., et al., EMBO J. (1992) 11:1553-1562.
Davies, M. V., et al., JBC (1991) 266:14714-14720.
Davies, M. V., et al.,J. Virology(1993) 67:1688-1692.
Gura,Science(1997) 278:1041-1042.
Haig, D.M., et al.Immunology(1998) 93:335-340.
He, B., et al. PNAS (1997) 94:843-848.
Ikeda, et al.,Nature Medicine(1999) 5:881-887.
Jackson-Hall, C.A., et al., “Induction of cell death by stimulation of protein kinase C in human epithelial cells expressing a mutant ras oncogene: a potential therapeutic target,”British Journal of Cancer, 78(5), pp. 641-651, 1998.
Jagus, R. and Gray M.M.,Biochimie(1994) 76:779-791.
Janes, P.W., et al.Oncogene(1994) 9:3601.
Katze, M. G., et al., EMBOJ (1987) 6:689-697.
Katze, M. G., et al.,Trends in Microbiology(1995) 3:75-78.
Kawagishi-Kobayashi, M. et al., MCB (1997) 17:4146-4158.
Khoobyarian, et al.,J. Surg. Oncol(1975) 7:421-425.
Lee, J.M., et al. PNAS (1993) 90:5742-5746.
Lee, T.G., et al., MCB (1994) 14:2331-2342.
Levitzki A.,Eur. J. Biochem. (1994) 266:1
Lowe, S.W., et al.,Science(1994) 266:807-810.
Mathews, et al.,J. Virol. (1991) 65:5657-5662.
Mills, N. E., eta l.,Cancer Res. (1995) 55:1444.
Mundschau, L.J., et al., “Oncogenic ras Induces an Inhibitor of Double-stranded RNA-depdendent Eukaryotic Initiation Factor 2α-kinase Activation,”J. of Biological Chemistry, vol. 267, No. 32, 1992, pp. 23092-23098.
Mundshau, L. J. and Faller, D. V.,Biochimie(1994) 76:792-800.
Nanduri, S., EMBO J. (1998) 17:5458-5465.
Proud, D. G., Trends in Biochemical Sciences (1995) 20:241-246.
Radman, A., et al., “Effect of Single-Base Substitutions in the Central Domain of Virus-Associated RNA I on Its Functions,”J. of Virology, vol. 69, No. 7, 1995, pp. 4299-4307.
Raybaud-Diogene H., et al.,J. Clin. Oncology(1997) 15(3):1030-1038.
Redpath, N. T. and Proud, D. G., Biochimica et Biophysica Acta (1994) 1220:147-162.
Strong, J. E., et al., EMBO (1998) 17:3351-3362.
Tanaka, N., et al., “Immunotherapy of a vaccinia colon oncolysate prepared with interleukin-2 gene-encoded vaccinia virus and interferon-alpha increases the survival of mice bearing syngeneic colon adenocarcinoma,”J. of Immuno. , vol. 16, No. 4, 1994 (Abstract).
Wiessmuller, L. and Wittinghofter, F., Cellular Signaling (1994) 6(3):247-267.
Williams, B. R.,Biochemical Society Transactions(1997) 25:509-513.
Wu., S., et al., “Identification and Requirement of Three Ribosome Binding Domains in dsRNA-Dependent Protein Kinase (PKR),”Biochemistry, vol. 3, No. 39, 1998, pp. 13816-13826.
Zhang, et al.,PNAS U.S.A. (1996) 93:4513-4518.
Andreansky, S.S., et al. (1996). The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc Natl Acad Sci USA 93(21):11313-11319.
Boviatsis, E.J., et al. (1994). Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Ther. 5:323-321.
Carroll, N.M., et al. (1997). The effect of ganciclovir on herpes simplex virus-mediated oncolysis. J Surg Res. 69(2):413-417.
Chahlavi, A., et al. (1999). Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia. 1(2):162-169.
Chung, R.Y., et al. (1999). B-mybpromoter retargeting of herpes simplex virus γ34.5 gene-mediated virulence toward tumor and cycling cells. J Virol. 73(9):7556-7564.
Kirn, D.H., and McCormick., F. (1996). Replicating viruses as selective cancer therapeutics. Mol Med Today 2(12):519-527.
Martuza, R.L., et al. (1991). Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252(5007):854-856.
Toda, M., et al. (1998). Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther. 9(15):2177-2185.

Affiliated with

Also associated with

Rating

Viruses for the treatment of cellular proliferative disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Viruses for the treatment of cellular proliferative disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Viruses for the treatment of cellular proliferative disorders will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3848532